Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | recruiting | Phase 1 | 40 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05879367 | Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma | recruiting | Phase 1 | 66 | Orbus Therapeutics, Inc.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 5, 2025source: clinicaltrials